Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

Core Viewpoint - Regulus Therapeutics has entered into an acquisition agreement with Novartis, with an initial cash payment of $7.00 per share and potential additional cash through a contingent value right, totaling up to approximately $1.7 billion, expected to close in the second half of 2025 [1][8][9] Company Updates - The company reported positive topline data from the fourth cohort of patients in the Phase 1b multiple-ascending dose study of farabursen for treating autosomal dominant polycystic kidney disease (ADPKD), indicating a mechanistic dose response and halting of kidney volume growth [3][4] - A pivotal Phase 3 trial is set to begin in the third quarter of 2025, with alignment confirmed with the FDA on trial design and endpoints [6][14] Financial Results - As of March 31, 2025, the company had $65.4 million in cash, cash equivalents, and short-term investments, with a cash runway expected to extend into early 2026 [10] - Research and development expenses for Q1 2025 were $6.8 million, up from $6.0 million in Q1 2024, while general and administrative expenses increased to $3.7 million from $2.8 million in the same period [11][12] - The net loss for Q1 2025 was $9.6 million, or $0.15 per share, compared to a net loss of $8.5 million, or $0.29 per share, in Q1 2024 [12][22]